Friday August 27, London

01.00 - 23.59
WCO-IOF-ESCEO
08.00 - 09.00
NON-SPONSORED SYMPOSIA
08.00 - 09.00
AVAILABLE INDUSTRY BREAKFAST SYMPOSIUM
08.00 - 09.00
AVAILABLE INDUSTRY BREAKFAST SYMPOSIUM
09.00 - 10.30
SCIENTIFIC SESSION I
Chairpersons: Cyrus Cooper, Jean‑Yves Reginster
09.00
Plenary Lecture 1
Management of musculoskeletal disease from cradle to grave Cyrus Cooper
09.30
Oral communication selected from abstracts
10.30 - 12.10
SCIENTIFIC SESSION II
Chairpersons: John A. Kanis, René Rizzoli
10.30
Presentation of the ESCEO-IOF Herbert Fleisch Medal
10.35
Presentation of the IOF President's Award
10.40
Plenary Lecture 2
Building bone strength with anabolic agents Michael R. McClung
11.10
Oral communication selected from abstracts
12.15 - 13.45
AVAILABLE INDUSTRY SATELLITE LUNCH SYMPOSIUM
14.00 - 15.00
MEET-THE-EXPERT SESSIONS
Transgender medicine, bone and muscle
Jean‑Marc Kaufman
Impact of glucocorticoids on bone and muscle
Evelien Gielen
HIV and bone
Emmanuel Biver
Is screening of osteoporosis useful?
E. M. Curtis
14.00 - 15.00
Poster Viewing Session I
14.00 - 15.10
Oral presentation of selected posters
14.00 - 15.00
Educational Lecture
Dietary patterns and fracture risk Stefania Maggi
14.00 - 15.00
ESCEO Symposium
‣ Determinants of the differences between the ESCEO and OARSI 2019 guidelines for the management of knee osteoarthritis
Chairpersons: Ali Mobasheri, Jean‑Yves Reginster
Similarities and differences between the OARSI and ESCEO guidelines for the management of knee osteoarthritis Tim McAlindon
How can we explain the differences between the OARSI and ESCEO guidelines for the management of knee osteoarthritis? Nigel K. Arden
Discussion (Leader: Olivier Bruyère) All
14.00 - 15.00
Update of the ESCEO recommendations for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia
Chairpersons: Charlotte Beaudart, Roger A. Fielding
Introduction Alfonso Cruz Jentoft
Patients to be included in clinical trials assessing the safety and efficacy of new chemical entities aiming at the treatment of sarcopenia Mario Miguel Rosa
Primary and secondary endpoints for clinical trials assessing the safety and efficacy of new chemical entities aiming at the treatment of sarcopenia Andrea Laslop
Discussion (Leader : Andrea Trombetti): All participants of the Working Group
Conclusion Jürgen Bauer
15.00 - 17.00
SCIENTIFIC SESSION III
Chairpersons: Radmila Matijevic, Manju Chandran
15.00
Plenary Lecture 3
Management of bone disease in cancer Robert E. Coleman
15.30
Oral communication selected from abstracts
16.30
Plenary Lecture 4
Thyroid, bone and cartilage G Williams
15.00 - 16.45
COMMITTEE OF NATIONAL SOCIETIES SPECIAL PLENARY SESSION
15.45
Presentation of the IOF Committee of National Societies Medal
17.00 - 18.30
AVAILABLE INDUSTRY SATELLITE SYMPOSIUM
17.00 - 18.30
AVAILABLE INDUSTRY SATELLITE SYMPOSIUM